1. Home
  2. TKO vs ABVX Comparison

TKO vs ABVX Comparison

Compare TKO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TKO Group Holdings Inc.

TKO

TKO Group Holdings Inc.

HOLD

Current Price

$184.40

Market Cap

13.9B

Sector

N/A

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$113.03

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKO
ABVX
Founded
1980
2013
Country
United States
France
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
11.9B
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
TKO
ABVX
Price
$184.40
$113.03
Analyst Decision
Strong Buy
Buy
Analyst Count
17
13
Target Price
$224.53
$131.31
AVG Volume (30 Days)
1.1M
818.6K
Earning Date
05-06-2026
03-23-2026
Dividend Yield
1.70%
N/A
EPS Growth
11200.00
N/A
EPS
2.46
N/A
Revenue
$4,735,151,000.00
N/A
Revenue This Year
$23.14
$52.14
Revenue Next Year
$1.05
$4,132.27
P/E Ratio
$74.93
N/A
Revenue Growth
68.85
N/A
52 Week Low
$176.00
$69.81
52 Week High
$226.94
$148.83

Technical Indicators

Market Signals
Indicator
TKO
ABVX
Relative Strength Index (RSI) 41.92 38.86
Support Level $180.23 $107.67
Resistance Level $190.19 $129.00
Average True Range (ATR) 5.25 3.46
MACD -1.10 -0.85
Stochastic Oscillator 6.27 7.56

Price Performance

Historical Comparison
TKO
ABVX

About TKO TKO Group Holdings Inc.

TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four activities: Media rights, production, and content, Live events and hospitality, Partnerships and marketing and Consumer products licensing, The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: